Morning Movers (GNOM, REGN, CHTP, KVHI, BDCO)

The three major US equities indexes opened higher this morning as traders respond positively to Greek parliament’s vote to accept additional austerity meausres in exchange for a second $172 bailout package. The DJIA is about up nearly 55 points at about 12,856, the Nasdaq Composite is up more than 25 points at about 2,929, and the S&P 500 is nearly 7 points at about 1,350.

There are several stocks trading more heavily than usual this morning, and also experiencing large gains or drops in share prices. These include Complete Genomics Inc. (NASDAQ: GNOM), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), KVH Industries Inc. (NASDAQ: KVHI), and Blue Dolphin Energy Co. (NASDAQ: BDCO).

After the first hour of trading this morning, Complete Genomics is up nearly 33% at $4.37. Volume is about already nearly 10x the daily average of about 675,000 shares traded. The DNA-sequencing company has been selected by the Mayo Clinic to supply outsourced whole human genome sequencing.

Regeneron is up about 11% at $113.27 after posting a new 52-week high of $115.50 earlier this morning. Volume is already about 8x the daily average of 615,000 shares traded. The biopharmaceutical company raised its full-year sales forecast.

Chelsea is down more than -34% at $3.28 after posting a new 52-week low of $2.90 earlier. Volume is already about 30x the daily average of about 680,000 shares traded. The development stage pharmaceutical company reported that it would present additional information for its new drug application currently pending before the FDA.

KVH is down nearly -9% at $9.04. Volume is already about half the daily average of around 62,000 shares traded. The mobile communications product maker provided lower-than-expected guidance for 2012 this morning.

Blue Dolphin is up nearly 16% at $5.97. Volume is already more than double the daily average of about 22,000 shares traded. The oil & gas midstream and E&P company sold $300 million of new notes in a private placement last week.

Paul Ausick